Valentin Garcia

Profesor Asociado

Universidad de Alcalá

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Eduardo Anguita Mandly

Professor (Profesor Titular)

Universidad Complutense de Madrid

SPAIN

View details

Elisabetta Abruzzese

UNIVERSITY TOR VERGATA

ITALY

View details

ROSA MARIA AYALA DIAZ

Full Professor

Universidad Complutense de Madrid

SPAIN

View details

Juan Carlos Hernandez-Boluda

University of Valencia

SPAIN

View details

Clara Sánchez Menéndez

Instituto de Salud Carlos III

SPAIN

View details

Tim Brümmendorf

Head

University Hospital RWTH Aachen

GERMANY

View details

Mayte Perez-olmeda

Instituto de Salud Carlos III

SPAIN

View details

Lorena Vigón Hernández

Instituto de Salud Carlos III

SPAIN

View details

Sara Rodríguez Mora

Instituto de Salud Carlos III

SPAIN

View details

Elena Mateos de las Morenas

Instituto de Salud Carlos III

SPAIN

View details

CARLO GAMBACORTI PASSERINI

Full Professor of Hematology

University of Milano-Bicocca

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Valentin Garcia

Research Interests

Explore related searches

Contact this professor

Articles (14)

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

Sustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to Avoid a Fatal Outcome

Regular Humoral and Cellular Immune Responses in Individuals with Chronic Myeloid Leukemia Who Received a Full Vaccination Schedule against COVID-19

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19

Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.

Collaborators (11)

Eduardo Anguita Mandly

Elisabetta Abruzzese

ROSA MARIA AYALA DIAZ

Juan Carlos Hernandez-Boluda

Clara Sánchez Menéndez

Tim Brümmendorf

Mayte Perez-olmeda

Lorena Vigón Hernández

Sara Rodríguez Mora

Elena Mateos de las Morenas

CARLO GAMBACORTI PASSERINI

Make your next move.